One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Discontinuation of Disease-Modifying Therapy in Multiple SclerosisShould We Stay or Should We Go?
Eva M. M. Strijbis, MD, PhD; Anne Kerbrat, MD, PhD; John R. Corboy, MD
doi : 10.1001/jamaneurol.2021.0764
JAMA Neurol. 2021;78(7):787-788
Helping the Public Understand Adverse Events Associated With COVID-19 VaccinationsLessons Learned From Functional Neurological Disorder
David Dongkyung Kim, MD; Candice S. Kung, MD; David L. Perez, MD, MMSc
doi : 10.1001/jamaneurol.2021.1042
JAMA Neurol. 2021;78(7):789-790
The Great Escape—A Physician Confronts Family Caregiving During the COVID-19 Pandemic
Lynn Hallarman, MD
doi : 10.1001/jamaneurol.2021.1170
JAMA Neurol. 2021;78(7):791-792
Bad Air and Parkinson Disease—The Fog May Be Lifting
E. Ray Dorsey, MD; Michael S. Okun, MD; Caroline M. Tanner, MD, PhD
doi : 10.1001/jamaneurol.2021.0863
JAMA Neurol. 2021;78(7):793-795
Ischemic Events After Intracerebral HemorrhageA New Target for Secondary Prevention
Graeme J. Hankey, MD
doi : 10.1001/jamaneurol.2021.0772
JAMA Neurol. 2021;78(7):795-797
Discontinuing Antiseizure Medication in Neonates With Acute Symptomatic Seizures—Primum non nocere
Eric T. Payne, MD, MPH; Elaine C. Wirrell, MD
doi : 10.1001/jamaneurol.2021.1218
JAMA Neurol. 2021;78(7):797-799
Association of NO2 and Other Air Pollution Exposures With the Risk of Parkinson Disease
Sungyang Jo, MD1; Ye-Jee Kim, PhD2; Kye Won Park, MD1; Yun Su Hwang, MD1; Seung Hyun Lee, MD1; Bum Joon Kim, MD, PhD1; Sun Ju Chung, MD, PhD1
doi : 10.1001/jamaneurol.2021.1335
JAMA Neurol. 2021;78(7):800-808
The development of Parkinson disease (PD) may be promoted by exposure to air pollution.
Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies
Santosh B. Murthy, MD, MPH1; Cenai Zhang, MS1; Ivan Diaz, PhD2; Emily B. Levitan, ScD3; Silvia Koton, PhD4,5; Traci M. Bartz, MS6; Janet T. DeRosa, MS7,8; Kevin Strobino, MS7,8; Lisandro D. Colantonio, MD, PhD3; Costantino Iadecola, MD1; Monika M. Safford, MD9; Virginia J. Howard, PhD3; W. T. Longstreth Jr, MD10,11; Rebecca F. Gottesman, MD, PhD4,12; Ralph L. Sacco, MD, MS13; Mitchell S. V. Elkind, MD, MS7,8; George Howard, DrPH14; Hooman Kamel, MD1,15
doi : 10.1001/jamaneurol.2021.0925
JAMA Neurol. 2021;78(7):809-816
Intracerebral hemorrhage and arterial ischemic disease share risk factors, to our knowledge, but the association between the 2 conditions remains unknown.
Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures
Hannah C. Glass, MDCM, MAS1,2,3; Janet S. Soul, MDCM4; Taeun Chang, MD5; Courtney J. Wusthoff, MD, MS6,7; Catherine J. Chu, MD8; Shavonne L. Massey, MD9,10; Nicholas S. Abend, MD, MSCE9,10,11; Monica Lemmon, MD12,13; Cameron Thomas, MD, MS14; Adam L. Numis, MD1,2; Ronnie Guillet, MD, PhD15; Julie Sturza, MPH16; Nancy A. McNamara, MD16; Elizabeth E. Rogers, MD2; Linda S. Franck, RN, PhD2,17; Charles E. McCulloch, PhD3; Renée A. Shellhaas, MD, MS16
doi : 10.1001/jamaneurol.2021.1437
JAMA Neurol. 2021;78(7):817-825
Antiseizure medication (ASM) treatment duration for acute symptomatic neonatal seizures is variable. A randomized clinical trial of phenobarbital compared with placebo after resolution of acute symptomatic seizures closed early owing to low enrollment.
Assessment of Recurrent Stroke Risk in Patients With a Carotid Web
Valeria Guglielmi, MD1; Kars C. J. Compagne, MD2,3; Amir Hossein Sarrami, MD3; Wouter M. Sluis, MD4; Lucie A. van den Berg, MD1; Pieter M. van der Sluijs, MD3; Daniel M. Mandell, MD5; Aad van der Lugt, MD3; Yvo B. W. E. M. Roos, MD1; Charles B. L. M. Majoie, MD6; Diederik W. J. Dippel, MD2; Bart J. Emmer, MD6; Adriaan C. G. M. van Es, MD7; Jonathan M. Coutinho, MD1; for the MR CLEAN trial and MR CLEAN Registry Investigators
doi : 10.1001/jamaneurol.2021.1101
JAMA Neurol. 2021;78(7):826-833
A carotid web (CW) is a shelf-like lesion along the posterior wall of the internal carotid artery bulb and an underrecognized cause of young stroke. Several studies suggest that patients with symptomatic CW have a high risk of recurrent stroke, but high-quality data are lacking.
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Jerry R. Mendell, MD1,2,3; Samiah A. Al-Zaidy, MD4; Kelly J. Lehman, MSN1; Markus McColly, BA1; Linda P. Lowes, PT, PhD1,2; Lindsay N. Alfano, PT, DPT1; Natalie F. Reash, PT, DPT1; Megan A. Iammarino, PT, DPT1; Kathleen R. Church, MSW1; Aaron Kleyn, PhD5; Matthew N. Meriggioli, MD5; Richard Shell, MD2,6
doi : 10.1001/jamaneurol.2021.1272
JAMA Neurol. 2021;78(7):834-841
This ongoing study assesses long-term safety and durability of response in infants with spinal muscular atrophy (SMA) type 1 after dosing with onasemnogene abeparvovec gene replacement therapy.
Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration
Alexander U. Brandt, MD1,2,3; Michael Sy, MD, PhD2; Judith Bellmann-Strobl, MD1,3; Barbara L. Newton, MD2; Judy Pawling4; Hanna G. Zimmermann, PhD1,3; Zhaoxia Yu, PhD5; Claudia Chien, MSc1,3; Jan Dörr, MD1,3; Jens Th. Wuerfel, MD1,6; James W. Dennis, PhD4,7; Friedemann Paul, MD1,3; Michael Demetriou, MD, PhD2,8
doi : 10.1001/jamaneurol.2021.1116
JAMA Neurol. 2021;78(7):842-852
N-glycan branching modulates cell surface receptor availability, and its deficiency in mice promotes inflammatory demyelination, reduced myelination, and neurodegeneration. N-acetylglucosamine (GlcNAc) is a rate-limiting substrate for N-glycan branching, but, to our knowledge, endogenous serum levels in patients with multiple sclerosis (MS) are unknown.
Clinicopathologic Features of Oculopharyngodistal Myopathy With LRP12 CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes
Theerawat Kumutpongpanich, MD1,2; Masashi Ogasawara, MD1,2; Ayami Ozaki, MD1,2; Hiroyuki Ishiura, MD, PhD3; Shoji Tsuji, MD, PhD3; Narihiro Minami, MSc1,2; Shinichiro Hayashi, PhD1,2; Satoru Noguchi, PhD1,2; Aritoshi Iida, PhD2; Ichizo Nishino, MD, PhD1,2; and the OPDM_LRP12 Study Group
doi : 10.1001/jamaneurol.2021.1509
JAMA Neurol. 2021;78(7):853-863
Repeat expansion of CGG in LRP12 has been identified as the causative variation of oculopharyngodistal myopathy (OPDM). However, to our knowledge, the clinicopathologic features of OPDM with CGG repeat expansion in LRP12 (hereafter referred to as OPDM_LRP12) remain unknown.
Encephalitis Induced by Immune Checkpoint InhibitorsA Systematic Review
Roser Velasco, MD, PhD1,2; Macarena Villagrán, MD3,4; Maria Jové, MD5; Marta Simó, MD, PhD1; Noelia Vilariño, MD1,5; Montserrat Alemany, MD1; Ramon Palmero, MD5; Maria Mercedes Martínez-Villacampa, MD6; Ernest Nadal, MD, PhD5; Jordi Bruna, MD, PhD1,2
doi : 10.1001/jamaneurol.2021.0249
JAMA Neurol. 2021;78(7):864-873
Encephalitis is a severe immune-related adverse event secondary to treatment with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) ranges from disease that resolves fully to lethal forms. Moreover, ICIs may unmask a paraneoplastic encephalitis. To our knowledge, the factors associated with ICI-iE prognosis are unknown
Flapping Scalp Sign as a Rare and Interesting Presentation in Delayed Postoperative Tension Pneumocephalus
Sunil Munakomi, MCh1; Binod Bhattarai, MCh1; Shashi Bhusan Sah, MS2
doi : 10.1001/jamaneurol.2021.1149
JAMA Neurol. 2021;78(7):874-875
Primary Central Nervous System Lymphoma With Symmetrical Pyramidal Tract Hyperintensity
Kaibin Shi, MD1,2; Junlin Shen, MD1,2; Xuanye Yue, MD1,2
doi : 10.1001/jamaneurol.2021.1165
JAMA Neurol. 2021;78(7):876-877
Sequential Bilateral Vision Loss in a Woman With Scalp Tenderness and Jaw Claudication
Aaron R. Kaufman, MD; Peter W. MacIntosh, MD; Brooke T. Johnson, DO
doi : 10.1001/jamaneurol.2021.0757
JAMA Neurol. 2021;78(7):878-879
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort
Zoé L. E. van Kempen, PhD1; Eva M. M. Strijbis, PhD1; Marissa M. C. T. Al, BSc1; Maurice Steenhuis, MSc2; Bernard M. J. Uitdehaag, PhD1; Theo Rispens, PhD2; Joep Killestein, PhD1
doi : 10.1001/jamaneurol.2021.1364
JAMA Neurol. 2021;78(7):880-882
